These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
263 related articles for article (PubMed ID: 30166208)
1. Rufinamide efficacy and safety in children aged 1-4 years with Lennox-Gastaut syndrome. Kim SH; Kang HC; Lee JS; Kim HD Brain Dev; 2018 Nov; 40(10):897-903. PubMed ID: 30166208 [TBL] [Abstract][Full Text] [Related]
2. Rufinamide for the treatment of Lennox-Gastaut syndrome: evidence from clinical trials and clinical practice. Striano P; McMurray R; Santamarina E; Falip M Epileptic Disord; 2018 Feb; 20(1):13-29. PubMed ID: 29313492 [TBL] [Abstract][Full Text] [Related]
3. Real-world data on rufinamide treatment in patients with Lennox-Gastaut syndrome: Results from a European noninterventional registry study. Nikanorova M; Brandt C; Auvin S; McMurray R Epilepsy Behav; 2017 Nov; 76():63-70. PubMed ID: 28927712 [TBL] [Abstract][Full Text] [Related]
4. Rufinamide as an adjuvant treatment in children with Lennox-Gastaut syndrome. Kim SH; Eun SH; Kang HC; Kwon EJ; Byeon JH; Lee YM; Lee JS; Eun BL; Kim HD Seizure; 2012 May; 21(4):288-91. PubMed ID: 22421185 [TBL] [Abstract][Full Text] [Related]
5. Long-term safety and seizure outcome in Japanese patients with Lennox-Gastaut syndrome receiving adjunctive rufinamide therapy: An open-label study following a randomized clinical trial. Ohtsuka Y; Yoshinaga H; Shirasaka Y; Takayama R; Takano H; Iyoda K Epilepsy Res; 2016 Mar; 121():1-7. PubMed ID: 26827266 [TBL] [Abstract][Full Text] [Related]
6. Dosing considerations for rufinamide in patients with Lennox-Gastaut syndrome: Phase III trial results and real-world clinical data. Kothare S; Kluger G; Sachdeo R; Williams B; Olhaye O; Perdomo C; Bibbiani F Seizure; 2017 Apr; 47():25-33. PubMed ID: 28284045 [TBL] [Abstract][Full Text] [Related]
7. Rufinamide as an adjunctive therapy for Lennox-Gastaut syndrome: a randomized double-blind placebo-controlled trial in Japan. Ohtsuka Y; Yoshinaga H; Shirasaka Y; Takayama R; Takano H; Iyoda K Epilepsy Res; 2014 Nov; 108(9):1627-36. PubMed ID: 25219353 [TBL] [Abstract][Full Text] [Related]
8. Rufinamide as add-on therapy in children with epileptic encephalopathies other than Lennox-Gastaut syndrome: A study of 34 patients. Caraballo RH; Pociecha J; Reyes G; Espeche A; Galichio S; Fasulo L; Semprino M Epilepsy Behav; 2020 Jul; 108():107074. PubMed ID: 32334364 [TBL] [Abstract][Full Text] [Related]
9. Rufinamide: a pharmacoeconomic profile of its use as adjunctive therapy in Lennox-Gastaut syndrome. McCormack PL Pharmacoeconomics; 2012 Mar; 30(3):247-56. PubMed ID: 22332960 [TBL] [Abstract][Full Text] [Related]
10. Safety and pharmacokinetic profile of rufinamide in pediatric patients aged less than 4 years with Lennox-Gastaut syndrome: An interim analysis from a multicenter, randomized, active-controlled, open-label study. Arzimanoglou A; Ferreira JA; Satlin A; Mendes S; Williams B; Critchley D; Schuck E; Hussein Z; Kumar D; Dhadda S; Bibbiani F Eur J Paediatr Neurol; 2016 May; 20(3):393-402. PubMed ID: 26805435 [TBL] [Abstract][Full Text] [Related]
11. Effectiveness and tolerability of rufinamide in children and young adults with Lennox-Gastaut syndrome: a single center study in Korea. Lee EH; Yum MS; Ko TS Clin Neurol Neurosurg; 2013 Jul; 115(7):926-9. PubMed ID: 23083943 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of rufinamide as adjunctive therapy in patients with Lennox Gastaut syndrome: A systematic review and Meta-analysis. Sharawat IK; Panda PK; Panda P; Dawman L Seizure; 2021 Oct; 91():296-307. PubMed ID: 34273668 [TBL] [Abstract][Full Text] [Related]
13. [Short-term efficacy and safety of rufinamide for Lennox-Gastaut syndrome]. Takayama R; Fukumura S; Minagawa K; Watanabe T No To Hattatsu; 2016 Sep; 48(5):322-6. PubMed ID: 30010275 [TBL] [Abstract][Full Text] [Related]
14. Rufinamide: a new antiepileptic medication for the treatment of seizures associated with lennox-gastaut syndrome. Wisniewski CS Ann Pharmacother; 2010 Apr; 44(4):658-67. PubMed ID: 20233912 [TBL] [Abstract][Full Text] [Related]
16. Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results. Laux LC; Bebin EM; Checketts D; Chez M; Flamini R; Marsh ED; Miller I; Nichol K; Park Y; Segal E; Seltzer L; Szaflarski JP; Thiele EA; Weinstock A; Epilepsy Res; 2019 Aug; 154():13-20. PubMed ID: 31022635 [TBL] [Abstract][Full Text] [Related]
17. Rufinamide in children and adults with Lennox-Gastaut syndrome: first Italian multicenter experience. Coppola G; Grosso S; Franzoni E; Veggiotti P; Zamponi N; Parisi P; Spalice A; Habetswallner F; Fels A; Capovilla G; Verrotti A; Mangano S; Balestri A; Curatolo P; Pascotto A Seizure; 2010 Nov; 19(9):587-91. PubMed ID: 20888268 [TBL] [Abstract][Full Text] [Related]
18. Adjunctive levetiracetam treatment in pediatric Lennox-Gastaut syndrome. Kim HJ; Kim SH; Kang HC; Lee JS; Chung HJ; Kim HD Pediatr Neurol; 2014 Oct; 51(4):527-31. PubMed ID: 25266616 [TBL] [Abstract][Full Text] [Related]
19. Rufinamide in children and adults in routine clinical practice. Jaraba S; Santamarina E; Miró J; Toledo M; Molins A; Burcet J; Becerra JL; Raspall M; Pico G; Miravet E; Cano A; Fossas P; Fernández S; Falip M Acta Neurol Scand; 2017 Jan; 135(1):122-128. PubMed ID: 26923380 [TBL] [Abstract][Full Text] [Related]
20. Treatment of Adults with Lennox-Gastaut Syndrome: Further Analysis of Efficacy and Safety/Tolerability of Rufinamide. McMurray R; Striano P Neurol Ther; 2016 Jun; 5(1):35-43. PubMed ID: 26861566 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]